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We report a case of recurrent occlusion of laser iridotomy (LI) sites after a Visian ICL (Implantable contact 
lens version 4, Staar Surgical AG, Nidau, Switzerland) implantation. A 45‐year‐old woman had bilateral ICL 
implantation after placement of two peripheral LI sites in each eye to prevent pupillary block. At one month 
after the operation, severe narrowing or occlusion of four LI sites occurred. After this, although she received 
four additional LIs at postoperative months 1, 6, 9 and 10 in both eyes, the narrowing or occlusion recurred. 
Mild chronic anterior chamber inflammation was observed intermittently throughout the follow‐up period. We 
performed clear lens extraction in both eyes (at postoperative month 11 in the left eye and month 26 in the 
right eye) due to recurrent occlusion of the LI sites and excess trabecular meshwork pigment deposition 
presumably caused by the four repeated LIs. Recurrent obstruction of LI sites can occur after ICL 
implantation. These problems were unresolvable despite four repeated laser iridotomies. The risks 
associated with anterior uveitis must be considered when planning an ICL implantation.
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Recently, ICL implantation has received attention for its 
excellent and rapid visual and refractive results in eyes with 
high myopia but there are still concerns about complications 
such as anterior capsule opacity cataracts,
1,2 pupillary block 
glaucoma,
3,4 chronic inflammation,
5 pigmentary dispersion 
syndrome,
6,7 and pigmentary glaucoma.
8 We report an interesting 
case of recurrent narrowing or obstruction of laser iridotomy 
(LI) sites despite four repeated procedures of LI.
Case Report
A 45‐year‐old woman, with refraction of ‐7.5 Dsph in the 
right eye (RE) and ‐9.25 Dsph ‐1.2 Dcyl×80° in the left eye 
(LE) presented as a good candidate for ICL implantation. 
With a thin central cornea thickness (450 µm), a sufficient 
anterior chamber depth (3.32 mm), a white‐to‐white diameter 
of 11.2 mm, a wide iridocorneal angle with light trabecular 
meshwork (TM) pigmentation, and no ocular disease such as 
cataracts, glaucoma, or uveitis, she was well within all 
indications for the procedure. She had mild dry eye 
symptoms and a history of occasional injection in both eyes 
that had improved spontaneously. She had no systemic 
disease such as diabetes.
After obtaining informed consent, two peripheral LIs were 
performed superiorly, approximately 90 degrees apart in each 
eye to prevent pupillary block. An argon green laser was 
used to make a definite and sufficiently sized opening (more 
than 500 µm in diameter) for the LI site. Also to prevent 
regrowth of the iris pigmented epithelium and to remove 
residual radial iris strands, an Nd: YAG laser was applied (1 
mJ, average of 5 pulses). Patent sites and adequate sizes were 
confirmed 1 day after LI and every follow‐up day after that 
with Goldmann 3 mirrors with 25x magnification. To reduce 
inflammation after the LI, 0.1% fluorometholone was 
administered four times daily for 3 days. Seven days after LI, 
a Visian ICL (ICM115V4 ‐11.00 diopter) was implanted in 
the RE and a ‐13.50 diopter lens of the same design was 
implanted in the LE. Two weeks after surgery, the 
uncorrected visual acuity (UCVA) was 25/20 with refraction 
of  ‐0.25 Dcyl×172° in the RE and ‐0.25 Dsph in the LE.
At postoperative 1 week, moderate inflammatory cells (+2) 
were found in the anterior chamber and vaulting (from the IK Park, et al, OCCLUSION OF LASER IRIDOTOMY SITES AFTER PHAKIC IOL
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Fig. 1. Laser iridotomy (LI) sites at 9 months after ICL 
surgery. Pinpoint openings (solid arrow) of LI sites with 
regeneration of dark‐brown iris pigment epithelium (hollow 
arrow) were observed. The Iris was distorted toward LI sites 
due to repeated LI. 25×, Goldmann 3 mirrors.
Fig. 2. Width of iridocorneal angle at 9 months after ICL surgery. (A) Peripheral iris was very steep and convex. Iridocorneal angle
was narrowed because of the obstruction of LI sites. (B) After additional LI, although the angle width increased, trabecular pigment
also increased. 25×, Goldmann 3 mirrors.
posterior surface of ICL to the anterior lens capsule) was 100
‐125% of the central corneal thickness (CCT) in both eyes. 
To control the inflammation, 0.1% fluorometholone was 
administered every 2 hours in both eyes. Unfortunately, the 
inflammatory cells of the anterior chamber did not resolve. 
As time passed, the iris pigments of the ICL and vaulting 
increased progressively. At one month postoperative, 70% 
narrowing or obstruction of all the 4 peripheral LI sites was 
observed in both eyes (Fig. 1). Inflammatory cells (+1) 
persisted in the anterior chamber despite the administration 
of 0.1% fluorometholone four times per day. The iridocorneal 
angle narrowed to less than 10 degrees and vaulting increased 
to approximately 250% of CCT in RE and 300% of CCT in 
LE. Intraocular pressure was 12 mmHg in RE and 10 mmHg 
in LE. After additional laser treatment, the angle width 
increased to 40 degrees and vaulting returned to 100% (Fig. 
2). Although 0.1% fluorometholone was administered four 
times daily for 7 days after LI, mild cells (+1) remained in 
the anterior chamber. When the more potent 1% prednisolone 
acetate was used, anterior inflammatory cells disappeared. 
Although she received three additional LIs (at postoperative 
months 6, 9 and 10) in both eyes, the narrowing or occlusion 
of the LI sites recurred. Mild inflammatory cells (+1) were 
observed transiently throughout the follow‐up period. Pigment 
deposits on the ICL were observed and pigmentation of TM 
increased to Grade 3 or 4 by the semi‐quantitative method 
(Grade 0‐4) due to the four repeated LIs. The pupil was 
distorted toward the LI site but posterior synechia was not 
observed. Finally, we removed the ICL and performed clear 
lens extraction (CLE) at postoperative month 11 in the LE 
and month 26 in the RE. After CLE, good UCVA (20/20) 
and normal intraocular pressure (12 mmHg) were well 
maintained but the distortion of the iris toward the LI sites 
remained. There was no evidence of pigment dispersion 
syndrome or pigmentary glaucoma.
Discussion
The aim of this report is to illustrate that recurrent 
obstruction of LI sites can be induced by ICL implantation 
and that these complications were unresolvable despite four 
repeated LI treatments.
LI is very important for the prevention of pupillary block. 
Because Asians have thicker and more heavily pigmented 
irises, formation of the LI site must be performed with a 
combined technique (using argon to make the initial bore and 
the Nd:YAG laser to complete the perforation)
9 and the size 
of LI sites must be larger than those in Caucasians. Kor J Ophthalmol Vol.22, No.2, 2008
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Ophthalmologists who do not have much experience with 
Asian patients may not know about the more consistent 
structure of this iris type, therefore performing LI on this 
population can be complicated. 
It is not certain whether ICL implantation itself might 
provoke anterior uveitis or if the patient had undiagnosed 
anterior uveitis in the past and it simply recurred after ICL 
implantation. We posit that the ICL was implanted during a 
quiescent period but the chronic irritation of the posterior iris 
surface by the ICL disrupted the anterior blood aqueous 
barrier, inducing anterior chamber inflammation. As a result, 
the iris pigment epithelium regenerated and occluded LI sites. 
There is convincing evidence found by ultrasound 
biomicroscopy that contact between the ICL and the posterior 
iris surface occurred in all cases. Jimenez‐Alfaro et al. 
reported that the aqueous flare can increase by 49.19% in the 
first postoperative month relative to preoperative values, then 
decrease and subsequently remain above preoperative values 
for 24 months.
5 There are many reports about subclinical 
inflammation after implantation of anterior chamber phakic 
IOLs.
10 However, subclinical inflammation after ICL 
implantation has not been as problematic as the decrease of 
lens transmission.
5 It is now necessary to focus our attention 
on the chronic rubbing of the posterior iris surface by the 
ICL and on subclinical inflammation, because chronic 
inflammation can induce cataracts, obstruction of LI sites, 
synechia, or cystoid macular edema. Therefore, it must be 
considered as a possibility even if inflammatory cells in 
anterior chamber are undetectable by the slitlamp, because 
flare and increased permeability of the blood‐aqueous barrier 
can be detected with a laser flare‐cell meter or by 
fluorophotometry. Determining the exact ICL size is crucial 
for the prevention of rubbing of the posterior surface of the 
iris with the ICL. The white‐to‐white distance was measured 
with a caliper and rechecked with ORBSCAN to be 11.2 mm. 
So the ICL was implanted with a horizontal length of 11.5 
mm. Because the vault was 100% of CCT at postoperative 
week 1, the size of the ICL seemed appropriate. 
The inflammation of the anterior chamber and the 
obstruction of LI sites occurred in both eyes nearly 
simultaneously with similar features. After CLE, the 
inflammation of the anterior chamber disappeared at 1 month 
postoperative and the size of the LI sites remained constant. 
Given these results, it would seem that the cause of the 
anterior uveitis in this patient was the ICL combined with a 
predisposition toward inflammation.
The pupil was distorted toward the LI sites due to multiple 
laser treatments and high energy transmission (Fig. 1). In our 
case, surgical pigment vacuum iridectomy
11 was considered 
before CLE because a dry vitrector with viscoelastics can be 
used under topical anesthesia. However, CLE was indicated 
due to the trabecular hyperpigmentation and chronic 
inflammation. The ICL was removed without any difficulty 
at postoperative months 11 (LE) and 26 (RE) because the 
ICL did not adhere to its surroundings despite multiple 
pigments on the ICL and repeated laser therapies. From these 
findings, collamer, the material constituting the ICL, seems 
to be biocompatible.
12
Recurrent obstruction of LI sites can be induced by ICL 
implantation by either the trauma of the surgery or by 
reactivation of quiescent anterior uveitis. We therefore 
recommend that the size of LI sites for ICL implantation be 
slightly larger than conventional LI sites, especially in Asian 
irises. The risk of anterior uveitis should always be 
considered. Lastly a detailed review of the past medical 
history and examination of the anterior chamber looking for 
inflammation must be performed.
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